This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

JOHN A. KOLMER, M.D.; HERMAN BROWN, B.Sc.

Arch Intern Med. 1942;69(4):636-646.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Until the discovery of sulfanilamide and its derivatives chemotherapy had little of proved value to offer in the treatment of staphylococcic infections. It is true that recoveries from staphylococcic septicemia in human beings have been ascribed to the intravenous administration of gentian violet, neutral acriflavine and various mercurial and other compounds, but none of these substances has materially reduced its high mortality and none has proved of value in the treatment of experimental infections of mice and rabbits under well controlled conditions.

Domagk¹ found the original prontosil (the hydrochloride of 4-sulfamido-2'-4'-diaminoazobenzene) somewhat effective in the treatment of experimental staphylococcic infections of mice and later reported² that better results were observed with uliron (a brand of dimethyldisulfanilamide; paraaminobenzenesulfonylparaaminobenzenedimethylsulfonamide). As shown in table 1, various investigators have found sulfanilamide, sulfapyridine (2- [paraaminobenzenesulfonamido]-pyridine) and, more recently, thiazole derivatives of sulfanilamide effective in varying degrees in the treatment of these experimental infections. . . . [Full Text PDF of this Article]

Author Affiliations
With the Technical Assistance of Anna M. Rule PHILADELPHIA

From the Research Institute of Cutaneous Medicine.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?